News & Updates

In patients with metastatic castration-sensitive prostate cancer, triplet therapy may be ideal for fit patients with synchronous (de novo) high-volume disease while the androgen pathway inhibitor (API) doublet combinations may be preferred for those with metachronous (recurrent) low-volume disease, according to the results of a meta-analysis.

Triplet therapy with darolutamide, androgen-deprivation therapy (ADT) and docetaxel improves overall survival (OS) by approximately 30 percent vs ADT plus docetaxel in most disease volume and risk subgroups of patients with metastatic hormone-sensitive prostate cancer (mHSPC), a post hoc analysis of the phase III ARASENS trial has shown.

A less invasive intravaginal device that facilitates bimanual uterine compression appears to work well in the treatment of postpartum haemorrhage, according to the results of a phase II trial.

Treatment with the oral Toll-like receptor 8 (TLR8) agonist selgantolimod once weekly for 24 weeks is well tolerated and generally safe in patients with chronic hepatitis B (CHB) under viral suppression, according to a recent study.

Two researchers from the Philippines have discovered a gene the connects breast cancer development to stress and body clock disruption. In a recent study, they have shown the mechanism behind hormone and circadian regulation of the tumour-suppressor gene, Krüppel-like factor 9 (KLF9), and its effect on breast cancer progression.

Prenatal exposure to plastic-derived chemicals, such as bisphenol A (BPA) and phthalates, tends to increase the risk of asthma, particularly in males, a study has shown.

Among the neurostimulation devices used in the treatment of generalized epilepsy, deep-brain stimulation performs better than vagus nerve stimulation at reducing seizure frequency, as reported in a study. On the other hand, while results for responsive neurostimulation are promising, further research is needed.

Early treatment with a single dose of pegylated recombinant IL-29 type III interferon (IFN), otherwise known as peg lambda, significantly reduced clinical events in the phase III TOGETHER study evaluating mostly vaccinated, acutely symptomatic COVID-19 outpatients.